Tatyana Kushner, MD, is an associate professor of medicine in the division of gastroenterology and hepatology at Weill Cornell Medicine.

Brelovitug Offers New Hope for Hepatitis D Treatment

As interest grows in therapeutic development for hepatitis D virus (HDV), understanding how clinical trial endpoints translate into meaningful patient benefit remains a critical focus for clinicians. Unlike more common liver diseases, HDV trials rely on well-defined surrogate markers that reflect both viral activity and liver health. These endpoints are not only essential for regulatory evaluation but also serve as key indicators of whether emerging therapies may alter the natural history of this aggressive disease.

In the phase 2b portion of the AZURE-1 study, investigational agent brelovitug demonstrated success against the US Food and Drug Administration (FDA)-specified composite primary endpoint, which includes at least a 2-log reduction in HDV RNA alongside normalization of alanine aminotransferase (ALT). In an interview with HCPLive, Tatyana Kushner, MD, emphasized that while this endpoint is considered a surrogate, it is strongly associated with clinically meaningful outcomes.

Check out part 1 of the interview with Kushner 

“We care about both,” she explained, pointing to the importance of reducing viral replication while simultaneously improving liver inflammation, as reflected by ALT levels.

In the study, brelovitug met the primary endpoint across multiple dosing arms, reinforcing its potential as a therapeutic option in a space where treatment choices remain extremely limited. Beyond the binary endpoint achievement, Kushner highlighted the continuous decline in HDV RNA over time among treated patients, suggesting that longer treatment durations could yield even greater response rates, a question that ongoing and future analyses will aim to address.

For both clinicians and patients, these improvements are more than abstract metrics. Virologic decline offers tangible reassurance that the virus is being suppressed, while normalization of ALT provides evidence of reduced liver inflammation. Kushner noted that patients are often highly attuned to these laboratory values, particularly after years of limited treatment options and persistently abnormal results. The hope is that these biochemical improvements will ultimately translate into downstream clinical benefits, including reduced fibrosis progression and lower risk of liver-related complications.

According to phase 2b findings, brelovitug was generally well tolerated, with the most commonly reported adverse events being injection site reactions, an expected finding for a subcutaneous therapy. Of note, the flu-like symptoms frequently associated with pegylated interferon were largely absent. This distinction could represent a meaningful advantage in real-world practice, where tolerability often limits treatment uptake and persistence.

The study population itself further underscores the significance of these findings. Kushner pointed out that AZURE-1 included patients with a broad range of disease severity, without strict limitations on baseline ALT levels or fibrosis stage. As a result, some participants had advanced liver disease, including compensated cirrhosis, and potentially significant portal hypertension. Despite this higher-risk population, brelovitug demonstrated both efficacy and tolerability, strengthening confidence in its potential applicability across a wide spectrum of patients.

Editors’ Note: Kushner reports relevant disclosures with Gilead, Abbvie, GSK, Ipsen, Mirum, and Madrigal.

US Centers for Disease Control and Prevention. Hepatitis D Basics. April 24, 2024. Accessed April 29, 2026. 

https://www.cdc.gov/hepatitis-d/about/index.html

Ghany MG, Pan CQ, Lok AS, et al. AASLD ISDA Practice Guideline on treatment of chronic hepatitis B. 

. Published online November 4, 2025. doi:10.1097/HEP.0000000000001549

Mirum Pharmaceuticals. Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus. April 27, 2026. Accessed April 29, 2026. 

https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-Announces-Primary-Endpoint-Met-in-Phase-2b-Portion-of-the-AZURE-1-Study-of-Brelovitug-in-Chronic-Hepatitis-Delta-Virus/default.aspx

Videos

Brelovitug achieved the FDA-specified primary endpoint for HDV RNA reduction and normalization of ALT in a phase 2b trial.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

AZURE-1: Brelovitug Meets Key Endpoints in Hepatitis D, With Tatyana Kushner, MD

Julie Silverstein, MD, is the medical director of the pituitary center and of the clinical trials unit and professor of medicine and neurological surgery at WashU Medicine.

Relacorilant Reduces HbA1c in Cushing’s Despite GLP-1 Treatment, With Julie Silverstein, MD

Relacorilant reduced hemoglobin A1c (HbA1c) by nearly 1% in patients with 

 and hyperglycemia despite ongoing GLP-1 treatment, according to a secondary analysis of the GRACE phase 3 clinical trial.

American Association of Clinical Endocrinology (AACE) Annual Meeting 2026

 in Las Vegas, Nevada, by Julie Silverstein, MD, medical director of the pituitary center and of the clinical trials unit and professor of medicine and neurological surgery at WashU Medicine. In an interview with 

, Silverstein discusses the complex pathway between excess cortisol and a plethora of long-term health detriments.

“There are multiple parts at play,” Silverstein told 

. “When you have excess cortisol, you have increased glyconeogenesis in the liver. This increased fasting glucose impairs interferon signaling, including GLP-1 receptor signaling. It leads to increased insulin resistance in the adipose tissue, decreasing uptake of glucose in the skeletal tissue.”

The original GRACE trial was a phase 3, double-blind, placebo-controlled, randomized-withdrawal study assessing the safety, efficacy, and pharmacokinetics of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes mellitus/impaired glucose intolerance (DM/IGT) and/or uncontrolled hypertension. Patients were excluded from the trial if they had non-endogenous hypercortisolism, uncontrolled, clinically significant hypo- or hyperthyroidism, poorly controlled hypertension, severe renal insufficiency, or poorly controlled diabetes mellitus.

In the open-label phase, patients were assigned to receive relacorilant in 100 mg capsules, increased sequentially to a maximum dose of 400 mg once daily; after 22 weeks, patients were then evaluated for inclusion in the randomized-withdrawal phase based on predefined hyperglycemia and hypertension response criteria. Eligible patients were then randomly assigned in a 1:1 ratio to either relacorilant or placebo for 12 weeks.

GRACE ultimately achieved its primary endpoint, as substantially more participants who were switched to placebo lost hypertension control versus those who stayed on relacorilant (odds ratio [OR], 0.17; 

 = 0.02). However, a subgroup of participants had hyperglycemia despite using GLP-1s or dual GIP/GLP-1s.

To that end, Silverstein and colleagues undertook this analysis to examine this subgroup. Patients taking GLP-1s or GIP/GLP-1s prior to and for ≥80% of the open-label phase were included in the trial. The team utilized a mixed model for repeated measures to analyze least squares mean change from baseline to the open-label period week 22 in HbA1c, weight, waist circumference, and body composition.

A total of 152 patients were enrolled in the open-label phase; of these, 28 had hyperglycemia despite using GLP-1s or GIP/GLP-1s. Baseline mean HbA1c, weight, and waist circumference were 8.5%, 108.4 kg, and 124.8 cm, respectively. Investigators recorded baseline tissue lean mass percentage at 53.2%. Among this group, relacorilant treatment led to substantial reductions in HbA1c from baseline (-0.9%; 95% CI, -1.6 to -0.3; 

“There are glucose receptor modulators being studied in other diseases,” Silverstein said. “Relacorilant, in fact, in combination with a chemotherapeutic agent, is FDA approved for the treatment of platinum resistant ovarian cancer; there’s a glucose receptor modulator being investigated for patients with MASH; I think there’s also a modulator being studied in patients with ALS. There seems to be lots of different areas where these could be used clinically.”

Editors’ Note: Silverstein reports disclosures with Xeris, Chiesi, Camurus, Ascendis Pharma, Bayer, Recordati, and others.

Silverstein J, Dobri G, Elenkova A, et al. Relacorilant Treatment Improves Glycemic Control Among Individuals With Cushing Syndrome (Endogenous Hypercortisolism) and Hyperglycemia on Glucagon-Like Peptide-1 Receptor Agonists: Insights From a Phase 3 Study. Abstract presented at the American Association of Clinical Endocrinology Annual Meeting 2026, Las Vegas, NV. April 22-24, 2026.

Corcept Therapeutics. A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome (GRACE). ClinicalTrials.gov Identifier: NCT03697109. Updated July 16, 2025. Accessed April 29, 2026. 

https://clinicaltrials.gov/study/NCT03697109

Silverstein addresses a secondary analysis of the GRACE trial, highlighting relacorilant’s efficacy in reducing cortisol in patients taking GLP-1 RAs.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Low-Dose Radiation Therapy Gains Traction in US, With Hirsch Sudhir Matani, MD

Low-dose radiation therapy (LDRT) is emerging in US clinical practice as a noninvasive option for chronic musculoskeletal pain, particularly osteoarthritis and other degenerative or inflammatory conditions, with early clinical experience suggesting meaningful pain reduction and a favorable safety profile in appropriately selected patients.

 Hirsch Sudhir Matani, MD, radiation oncologist at Keck Medicine of USC, described LDRT as a long-established treatment in Europe that is beginning to gain renewed interest in the United States as awareness increases and supporting clinical data continue to accumulate. Adoption in the United States has historically been limited, reflecting differences in training and referral patterns.

“I guess the main reason why it hasn't been adopted as broadly [in the US] is the landscape of healthcare and the differences that are our systems compared with Europe,” Matani said.

Matani noted that increasing engagement from professional societies, including the American Society for Radiation Oncology (ASTRO), has contributed to renewed discussion regarding the role of radiation therapy in nonmalignant disease states.¹ As clinicians reassess nonpharmacologic options for chronic pain, LDRT is being reconsidered within multidisciplinary care models.

A key distinction between LDRT and oncologic radiation therapy lies in dose and biologic effect. Cancer treatment commonly involves cumulative doses in the range of approximately 50 to 80 Gy, depending on tumor type and treatment intent. In contrast, LDRT for benign disease typically uses low single-digit gray doses, often around 3 Gy, delivered in limited fractions. At these lower doses, radiation is thought to exert anti-inflammatory rather than cytotoxic effects.

Clinically, LDRT is most commonly applied in conditions such as osteoarthritis, plantar fasciitis, Dupuytren contracture, and Ledderhose disease. Patient selection generally focuses on individuals with persistent symptoms despite conservative management, often defined as ≥ 6 months of ongoing pain that has not responded adequately to nonsteroidal anti-inflammatory drugs, physical therapy, or intra-articular injections.

Across published European experience and institutional reports, approximately 60% to 80% of patients experience some degree of pain improvement following LDRT, ranging from partial relief to more substantial functional improvement.2 Research has shown that pain relief has lasted up to 2 years.3 Available evidence suggests a low incidence of adverse effects with low-dose LDRT.

Standard care for osteoarthritis and related conditions typically includes pharmacologic therapies such as NSAIDs or corticosteroids, physical therapy, and, when appropriate, surgical referral.

“We generally treat patients [with LDRT) who are either not surgical candidates or don't want surgery, and they've tried some other interventions that haven't really worked,” Matani said. “I could see that evolving over as we in the US…get more used to using low-dose radiation and as primary care providers and other doctors see that it works with limited side effects.”

Reported disclosures for Matani include Icotec Medical Inc. and GlaxoSmithKline, LLC.

Low-dose radiation therapy offers substantial relief to people with painful knee osteoarthritis - American Society for Radiation Oncology (ASTRO). ASTRO. Published September 28, 2025. 

https://www.astro.org/news-and-publications/news-and-media-center/news-releases/2025/low-dose-radiation-therapy-offers-substantial-relief-to-people-with-painful-knee-osteoarthritis

Hoveidaei A, Karimi M, Salmannezhad A, Tavakoli Y, Taghavi SP, Hoveidaei AH. Low-dose Radiation Therapy (LDRT) in Managing Osteoarthritis: A Comprehensive Review. 

. 2025;102:100777. Published 2025 Feb 12. 

Low-dose Radiation Therapy | Texas Oncology. Texasoncology.com. Published 2026. Accessed April 29, 2026. 

https://www.texasoncology.com/cancer-care/low-dose-radiation-therapy

Low-dose radiation therapy is gaining attention in the US for osteoarthritis and inflammatory pain, with clinicians citing anti-inflammatory effects.

Internal Medicine

Internal Medicine condition center page, resources on the topics of medical news and expert insight into internal medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on internal medicine research, treatment, and drug development.

Hospital Medicine

The HCPLive hospital medicine page is a comprehensive resource for clinical news and insights on the emergency medicine specialty. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for emergent care, and more.

Strategic Alliance Partnership

Baba Inusa, MBBS, is a Consultant Paediatrician in the School of Life Course & Population Sciences at King's College London.

Using SWAY’s Global Sickle Cell Data to Close Access, Treatment Gaps

Multinational data from SWAY points to an increased incidence of sickle cell in Sub-Saharan Africa despite persistent gaps in treatment access.

Senior study investigator Baba Insusa, MBBS, points clinicians toward actionable solutions, including global support for medications like hydroxyurea and penicillin, along with collaboration between sub-Saharan Africa (SSA), low- and middle-income countries (LMICs), and high-income countries (HICs), in this interview with 

The SWAY data analysis aimed to compare the impact of sickle cell disease—including symptoms, complications, and quality of life—on patients in SSA compared with those in LMICs and HICs.

The study included 2,145 patients aged 12 years and older across three regions: SSA (n = 519), LMICs (n = 422), and HICs (n = 1,204). Patients in SSA were younger overall, with a median age of 15 years, compared with 19 years in LMICs and 29 years in HICs.

“Funding is very important, but what we really need is a joined-up approach that provides a standard framework countries can use—so we can learn from each other and apply best practices across the board,” Inusa said.

Catch up with Part 1 of our conversation here!

Across regions, patients reported broadly similar symptom patterns and complications, suggesting a consistent global clinical phenotype of sickle cell disease. The most common symptoms included fatigue (34%–77%), headache (39%–58%), and bone aches (32%–58%), while complications such as fever (60%–75%), infections (37%–66%), and joint-related issues (29%–65%) were also consistently observed, reinforcing the multisystem burden of disease.

Despite this consistency, differences emerged in acute disease burden and treatment access. More than five vaso-occlusive crises (VOCs) in the prior year were reported in 30% of patients in SSA, compared with 22% in LMICs and 27% in HICs, notably within a younger SSA cohort. Treatment utilization also varied substantially, with lower opioid (26%) and over-the-counter analgesic use (30%) in SSA compared with HICs (73% and 64%, respectively), highlighting disparities in access and care delivery.

Expanding Access Through Essential Medicines

He emphasized that improving access to foundational therapies like hydroxyurea and penicillin should be a global priority, noting that positioning them as essential medicines—and securing support from major funding bodies—could reduce costs and improve both access and utilization.

He highlighted the need for more structured care systems, in which specialist centers are supported by generalist sites with the capacity to treat patients appropriately, helping expand access while maintaining quality of care.

He underscored the importance of incorporating patient perspectives into care and research, noting that symptoms like fatigue—historically underrecognized—are now being identified by patients as a major burden.

Looking Beyond Pain in Sickle Cell Disease

While pain remains central, he stressed that sickle cell disease extends beyond pain alone, pointing to organ damage and broader quality-of-life impacts as critical areas for both care and research.

Driving Investment and Global Collaboration

He concluded that improving outcomes will require stronger investment and collaboration across countries, organizations, and stakeholders, alongside continued efforts to standardize care frameworks and expand access globally.

“There is enough in this study to show we need better access, better investment, and prioritization of these treatments as essential medicines,” he concluded.

Editor’s Note: Inusa reports relevant disclosures with Novo Nordisk A/S.

Inusa B, Andemariam B, Minniti C, et al. Sickle Cell Disease Burden in Sub-Saharan Africa Compared to Other Regions: Results from the SWAY Survey. 

. Published online April 2026:100092. doi:

https://doi.org/10.1016/j.bglo.2026.100092

Inusa B. Increased Sickle Cell Pain Burden in Sub-Saharan Africa Despite Younger Patients. HCPLive. Published April 28, 2026. Accessed April 29, 2026. 

https://www.hcplive.com/view/increased-sickle-cell-pain-burden-in-sub-saharan-africa-despite-younger-patients

Inusa discusses how clinicians can close gaps in sickle cell disease care and global disparities. 

Hematology

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Using SWAY’s Global Sickle Cell Data to Close Access, Treatment Gaps 

Shashank Joshi, MD, is a consultant endocrinologist at Liavati Hospital and Joshi Clinic in Mumbai.

Navigating Iodine Deficiencies and Excesses in Thyroid Health, With Shashank Joshi, MD

 risk from both under- and overconsumption, iodine intake must be carefully monitored – particularly given the small doses hidden in many popular supplements.

 in Las Vegas, Nevada, by Shashank Joshi, MD, a consultant endocrinologist at Lilavati Hospital and Joshi Clinic in Mumbai, this talk details the risks of both excess iodine and iodine deficiency. Joshi highlights the various diseases born from iodine’s interaction with the thyroid, triggered both by too little and too much iodine in the system.

“Iodine biology becomes immunology. So, what happens when you have too much iodine or too little iodine?” Joshi told 

 in an exclusive interview. “The iodine behaves like an immunogen, and the body identifies it as an immunogen, and it attacks it through antibody production. If there is downregulation, then you get hypothyroidism or Hashimoto’s thyroiditis. If it’s upregulated, you will have Graves’ disease.”

Iodine deficiency is a well-studied contributor to goiter and hypothyroidism, as it plays a direct role in the production of thyroid hormone. Mild-to-moderate iodine deficiency can potentially be compensated by increased thyroid activity; however, chronic stimulation of the thyroid eventually increases the prevalence of toxic nodular goiter and hyperthyroidism. Additionally, iodine deficiency can directly impair cognitive function, as thyroid hormones are required for neuronal migration, glial differentiation, and myelination of the central nervous system.

However, the other side of the coin is similarly damaging. Iodine excess, the less-studied extreme of iodine intake, can lead to Graves’ disease and Hashimoto’s thyroiditis, both of which are driven by immune cell polarization and alterations in gut microbiota. The risk of cardiovascular diseases like hypertension and atherosclerosis is also increased due to endothelial dysfunction, inflammation, and oxidative stress. Further down the line, the development of thyroid cancer can also be influenced by excess iodine, as can learning and memory through neurotoxic effects.

To address these potential outcomes, Joshi highlights a narrow iodine window, pointing out the thyroid’s intolerance of extremes in either direction. He notes a bell curve in the biology of iodine, with early symptoms of both insufficient and excessive iodine intake appearing similar. The optimal range of iodine for thyroid health, therefore, occupies a relatively narrow space.

Additionally, Joshi points out the risk of iodine excess posed by everyday intake. Micronutrient supplements, despite being widely used and sold over the counter, are not directly approved by the US Food and Drug Administration (FDA). Because of this, they lack warnings for excess iodine content and can thus stealthily raise levels in a patient’s body. Additionally, iodized salt has become popular over the last few years, leading to another prominent source of iodine without any kind of warning on the risks of excess.

“Whenever a patient is taking any supplement over the counter, they need to read the label and see how much iodine is contained in it,” Joshi said. “You’re taking iodine sometimes through your salt, through your food, and an extra supplement could be creating that perfect storm which you want to avoid. Remember that excess thyroid production or cancer can be a byproduct of excess iodine intake.”

Editors’ Note: Joshi reports disclosures with Abbott, Lilly, Novo Nordisk, Sanofi, Torrent, Celagenex, and others.

Joshi S. Impact of Iodine on Thyroid Autoimmunity, Goiter and Oncogenesis (Hossein Gharib, MD, Lectureship). Presented at the American Association of Clinical Endocrinology Annual Meeting 2026, Las Vegas, NV. April 22-24, 2026.

Zimmermann MB, Boelaert K. Iodine deficiency and thyroid disorders. 

Khudair A, Khudair A, Niinuma SA, Habib H, Butler AE. Beyond thyroid dysfunction: the systemic impact of iodine excess. 

Joshi explains the narrow window of optimal iodine levels, highlighting the risk posed by supplements and iodized salt in tipping the scales toward health risks.

Thyroid Disorders

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Articles

The International Eczema Council set out to create a set of consensus-based definitions of remission, LDA, and vLDA in atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

International Eczema Council Releases Definitions of Remission, Low Disease Activity

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Expert panel weighs IL‑17 vs IL‑23 biologics for psoriasis, highlighting fast onset, durability, and why switching within class may work.

Video Series

IL-17 Inhibition and Long-Term Outcomes in Psoriasis

Professor of Medicine and Renal Division Chief at the University of Pennsylvania Perelman School of Medicine

Campbell answers questions about the current research and clinical landscape of APOL1-mediated kidney disease. 

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

APOL1 Reaches Turning Point While Clinical, Equity Challenges Persist, With Kirk Campbell, MD

Comparing Biologic Classes and Durability in Psoriasis

Christopher G. Bunick, MD, PhD, is an associate professor of dermatology at Yale University School of Medicine.

This Q&A interview highlights emerging therapies for atopic dermatitis, featuring Christopher G. Bunick, MD, PhD of Yale Medicine.

Positive Signals for Bispecific and Trispecific Antibodies in Atopic Dermatitis, With Christopher Bunick, MD, PhD

Brelovitug met the primary endpoint for virologic response and ALT normalization in the phase 2b portion of the AZURE-1 trial.

New Phase 2b AZURE-1 Data Signal Progress in Chronic Hepatitis D Treatment, With Tatyana Kushner, MD

Martina J. Porter, MD, is a dermatologist at Beth Israel Deaconess Medical Center.

54-week STOP-HS safety data for the JAK1-selective inhibitor povorcitinib showed no dose-dependent safety signal and few laboratory abnormalities.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Contextualizing JAK Safety With Povorcitinib in HS, With Martina Porter, MD

Endocrinology experts compare pediatric and adult growth hormone deficiency—causes, testing, MRI use, and transition care tips to improve outcomes.

Recognizing Growth Hormone Deficiency — Symptoms, Presentation, and Quality of Life

Experts compare pediatric vs adult growth hormone deficiency—causes, testing, MRI use, and why retesting matters during transition to adult care.

Unraveling Growth Hormone Deficiency — Etiology and Prevalence

Study investigator Inusa explains the gap in sickle cell disease findings from SWAP, a multinational survey. 

Latest News

AZURE-1: Brelovitug Meets Key Endpoints in Hepatitis D, With Tatyana Kushner, MD

Relacorilant Reduces HbA1c in Cushing’s Despite GLP-1 Treatment, With Julie Silverstein, MD

Low-Dose Radiation Therapy Gains Traction in US, With Hirsch Sudhir Matani, MD

Using SWAY’s Global Sickle Cell Data to Close Access, Treatment Gaps

Navigating Iodine Deficiencies and Excesses in Thyroid Health, With Shashank Joshi, MD